Detalles de la búsqueda
1.
Pharmacodynamic evaluation and safety assessment of treatment with antibodies to serum amyloid P component in patients with cardiac amyloidosis: an open-label Phase 2 study and an adjunctive immuno-PET imaging study.
BMC Cardiovasc Disord
; 22(1): 49, 2022 02 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-35152886
2.
Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component.
N Engl J Med
; 373(12): 1106-14, 2015 Sep 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-26176329
3.
An observational, non-interventional study for the follow-up of patients with amyloidosis who received miridesap followed by dezamizumab in a phase 1 study.
Orphanet J Rare Dis
; 17(1): 259, 2022 07 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35810311
4.
Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Intravenous Dose of Miridesap in Healthy Japanese Subjects.
Clin Pharmacol Drug Dev
; 8(5): 612-618, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-30556959
5.
Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis.
Sci Transl Med
; 10(422)2018 01 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29298867
6.
The effect of intravenous infusion of adenosine on electrically evoked hyperalgesia in a healthy volunteer model of central sensitization.
Anesth Analg
; 99(3): 816-822, 2004 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-15333416
Resultados
1 -
6
de 6
1
Próxima >
>>